Stabilized and lyophilized formulation of anthracycline compounds
View Patent ↗The present invention provides a lyophilized amrubicin formulation and a process thereof. In the process, the concentration of the aqueous solution before lyophilization is controlled to about 7.5 mg(potency)/mL or more. Thus, the formulation decreases the production of desaccharified compound and is stable to storage for a long period. The formulation is useful as a cancer chemotherapeutic agent.
1. A process for preparing a lyophilized amrubicin formulation comprising the following Steps (1) to (3):
(1) preparing an aqueous solution comprising (a) amrubicin or a pharmaceutically acceptable salt thereof and (b) L-cysteine or a salt thereof wherein the concentration of amrubicin or a pharmaceutically acceptable salt thereof is in the range of 7.5 mg(potency)/mL to 30 mg(potency)/HmL,
(2) sterilizing the aqueous solution of Step (1) by filtration, and
(3) lyophilizing the aqueous solution obtained in Step (2).
2. The process of claim 1 wherein the salt of L-cysteine is a hydrochloride thereof.
3. The process of claim 1 or 2 wherein the salt of amrubicin is a hydrochloride thereof.
4. The process of claim 1 wherein the concentration of amrubicin or a pharmaceutically acceptable salt thereof in the aqueous solution in Step (1) is in the range of 7.5 mg(potency)/mL to 25 mg(potency)/mL.
5. The process of claim 1 , wherein the aqueous solution of Step (1) further comprises an excipient.
6. The process of claim 5 wherein the excipient is lactose.
7. The process of claim 1 , wherein the salt of amrubicin is a crystalline amrubicin hydrochloride showing main peaks in a powder X-ray diffraction pattern at the diffraction angles (2θ) of 6.3 ±0.3, 10.1 ±0.3, 20.3 ±0.3, 26.5 ±.3 and 26.9 ±0.3.
8. A lyophilized formulation comprising amrubicin or a pharmaceutically acceptable salt thereof which is prepared by lyophilizing an aqueous solution comprising amrubicin or a pharmaceutically acceptable salt thereof in the range of 7.5 mg potency)/mL to 30 mg(potency)/mL, and wherein the lyophilized formulation further comprises L-cysteine or a salt thereof.
9. The lyophilized formulation of claim 8 , wherein the L-cysteine or a salt thereof is contained in the range of 0.5 mg to 250 mg per 100 mg (potency) of amrubicin or a salt thereof.